wicsu 2006 cancer report

8/6/2019 WICSU 2006 Cancer Report

1/12

WCISU ANNUAL PUBLICATION

No. SA6/01

Cancer Incidence in Wales 2000-2004

19th April 2006


2/12

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

TABLE OF CONTENTS

1.

FOREWORD............................................................................................................ 2

2. REGISTRATION OF CANCER IN WALES.............................................................. 32.1 ONS SUBMISSION........................................................................................... 4

2.2 DATA QUALITY ................................................................................................ 4

3. DEFINITIONS AND STATISTICAL METHODS....................................................... 53.1 CALCULATION OF INCIDENCE RATES AND AGE STANDARDISATION...... 5

3.2 STANDARD POPULATIONS............................................................................ 5

4. INCIDENCE FIGURES IN WALES BY SEX AND FIVE YEAR AGE GROUP 2004 74.1 MALES.............................................................................................................. 7

4.2 FEMALES ......................................................................................................... 8

5. TRENDS IN WALES 2000-2004 .............................................................................. 96. CRUDE RATES PER 100,000 POPULATION IN WALES 2000-2004 .................. 107. EASR PER 100,000 POPULATION IN WALES 2000-2004 .................................. 11


3/12


1. FOREWORD

The Welsh Cancer Intelligence & Surveillance Unit (WCISU) has published Cancer Incidence

Statistics for the diagnosis year 2004. As we have previously noted cancer registration is a

dynamic process based upon the consolidation of multiple sources of data on patient contacts

with the database. There is an ongoing process of statistical analysis and case note validation.

Previously in 2005 we reported our concerns with the PEDW data stream. This is not a purpose

made extract as used in most other registries but a routine dataflow based on PAS systems.

Changes in clinical practice may impact on codes e.g. transfer from inpatient or day case to

outpatient, with consequences for data capture. Resource limitations in Trusts may delay

transfers. WCISU have to filter off the relevant new data posing a considerable burden of data

processing.

However PEDW is an invaluable source of data especially on demographics and in collaboration

with Trusts, WCISU provides valuable feedback on Quality Assurance which hopefully enhances

its value for other users.

We are now receiving our first data flows from CaNISC, the all Wales cancer information system

now under the auspices of Informing Health Care. This should enable us to provide better quality

clinical data.

Our impression of these 2004 data is that the majority of sites are well within tolerance as

compared to the situation with the 2003 data and we are happy to publish them.

I thank the other members of the team for all their hard work and diligence in getting these

figures prepared.

J A Steward MBBCh BA MSc PhD FFPH

2


4/12


2. REGISTRATION OF CANCER IN WALES

The Welsh Cancer Intelligence and Surveillance Unit (WCISU) is tasked under its SLA with theWelsh Assembly Government to register all incidence of cancer for the resident population ofWales wherever they are treated. It is essential therefore to ensure completeness of registrationthat all possible sources of data collection are used. The use of multiple sources of data meansthat information relating to the same cancer incidence is received, and this also enhances thedata quality as different data items are brought together to form a single record. WCISU benefitsfrom a sophisticated computer package and a highly trained workforce to ensure that duplicateregistrations are avoided.

For the most recent year reported (2004) multiple notifications were received from:-

PEDW * records : Trusts throughout Wales: NHS Clearing Service

Pathology records : 13/14 Trusts

Extra Regional Notification ONS ** : Cancer Deaths

: Non Cancer Deaths

* Patient Episode Database Wales** Office of National Statistics

Table 1 illustrates the number of records processed for the calendar year 2004. Electronicprocessing and manual intervention by registration officers provide the resulting registrations for2004 incidence.

Table 1: Notification received by WCISU 2004

SOURCE NUMBER OF RECORDS RECEIVEDPEDW - Wales data

- English dataPathologyOther RegistriesDeath Certificates:

CancerNon Cancer

347960*NA

52454NA

96224393

Total Records ReceivedResulting in:

Total RegistrationAll Malignancies ex. skin

414429

2387420868

* Figures are high due to resubmissions from NHS Trusts.NA Not available at time of publication

3


5/12


2.1 ONS SUBMISSION

During the first years after being established WCISUs emphasis was concentrated ontimeliness. However since the inherited backlog of data has been cleared more time andresource has been given to ensuring the quality, not only of the data currently being registered,but also of previous registrations.

Registrations are submitted to ONS to enable flagging on NHS CR which in turn enables cancerregistries to receive Death Certificate Information. Cancer Registries are expected to have nomore than 0.5% status 3 records (ie. records containing serious errors) for each year submitted.Good quality record submission enables a high percentage of records to be traced on NHSCR.Table 2 shows WCISU submission to ONS and also is an indicator of the work that has beenundertaken to assure its quality.

Table 2: WCISU submissions to ONS

Year of Diagnosis Registrations* Status 3 % Traced records %20002001200220032004

15,41615,58315,60216,11316,587

0.00.00.00.00.0

99.999.999.799.894.1

* All malignancies ex. Skin (C44) and all D codesSource : ONS Management Report, December 2005

2.2 DATA QUALITY

The quality of the information produced by WCISU can only be maintained at the highest level ifall staff are involved in ensuring data quality at every process undertaken.

Validation rules are embedded into the software used for registration and these arereviewed in conjunction with the United Kingdom association of Cancer Registries andthe Office for National Statistics and updated as necessary.

Quality checks are run on incoming data to identify any quality issues.

Multiple sources of data are used for registration and any discrepancies between datasources are investigated to ensure data quality.

Regular data validation is undertaken by the Units staff who access original sourcedocumentation at hospitals by accessing medical records and verifying data received.

Analysis of data in response to requests for information and in preparation of publicationsincludes analysis staff in the quality program by highlighting any anomalies in the datathat are then passed for further validation.

4


6/12


In an effort to maintain good standards of incoming data, WCISU has developed and deliveredtraining packages to cancer information staff across Wales. Staff from the Unit who have beentrained as Clinical Coding Tutors also participate in the delivery of basic clinical coding to staffacross Wales and jointly develop, with the All Wales Coding Tutor, neoplasm workshops asfurther training for coding staff.

3. DEFINITIONS AND STATISTICAL METHODS

3.1 CALCULATION OF INCIDENCE RATES AND AGE STANDARDISATION

Crude Rate: This is the total number of cases registered per year as a proportion of the totalpopulation. It is usually quoted per 100,000 population.

Rates for older age groups are in general, much higher than those for younger people, so that

the crude rate for an area is very much influenced by the age structure of the population of thatarea. This means that comparisons of the crude rates between populations with different agestructures can be misleading. For this reason, methods have been developed to age-standardise cancer incidence rates.

Direct Standardisation: Age specific incidence rates from the population under study areapplied to a standard reference population to obtain the number of cases that would arise in thestandard population in each group. These are summed to obtain the overall directlystandardised incidence rate expressed per 100,000 population.

The standard hypothetical population used in this report the "European Standard Population"is shown in Table 3:

3.2 STANDARD POPULATIONS

The European Age Standardised Rate (E.A.S.R.) for Wales per 100,000 population is calculatedby applying age specific rates for Wales to the relevant standard European population shownabove. These are then summed across all age groups to obtain the overall E.A.S.R.

Because the age structure of the Welsh population differs from that of the European standardpopulation, the standardised rate for Wales, for any particular type of cancer will differ from thecrude rate. In general, because the Welsh population is slightly older than the Europeanstandard, the effect will be to lower the crude rate.

5


7/12


6

Table 3: European Standard Population

Age Group European

Under 5 8000

5-9 7000

10-14 7000

15-19 7000

20-24 7000

25-29 7000

30-34 7000

35-39 7000

40-44 7000

45-49 7000

50-54 7000

55-59 6000

60-64 500065-69 4000

70-74 3000

75-79 2000

80-84 1000

85 and over 1000

All ages 100,000


8/12


4. INCIDENCE FIGURES IN WALES BY SEX AND FIVE YEAR AGE GROUP

4.1 MALES

ICD10 Code Site 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64

C00-C14 Total lip, oral cavity and pharynx 0 0 0 1 0 0 0 3 12 18 33 34 31 C00 Lip 0 0 0 0 0 0 0 0 0 1 4 2 1

C01-C02 Tongue 0 0 0 1 0 0 0 1 2 7 9 8 14

C03-C06 Mouth 0 0 0 0 0 0 0 2 4 3 11 6 6

C07-C08 Salivary glands 0 0 0 0 0 0 0 0 0 0 1 2 1

C09-C10 Oropharynx 0 0 0 0 0 0 0 0 6 4 4 10 6

C11 Nasopharynx 0 0 0 0 0 0 0 0 0 1 0 0 0

C12-C13 Hypopharynx 0 0 0 0 0 0 0 0 0 2 2 4 3

C14 Pharynx unspecified 0 0 0 0 0 0 0 0 0 0 2 2 0

C15 Oesophagus 0 0 0 0 0 0 0 3 3 13 8 21 29

C16 Stomach 0 0 0 0 0 0 1 5 0 8 17 25 34

C17 Small intestine 0 0 0 0 0 0 0 0 1 0 1 3 2

C18-C21 Colorectal 0 0 0 0 1 0 3 2 12 23 46 94 124

C18 Colon 0 0 0 0 1 0 3 2 5 13 26 46 74

C19-C21 Rectum 0 0 0 0 0 0 0 0 7 10 20 48 50

C22 Liver and intrahepatic bile ducts 1 0 0 1 1 0 0 0 2 4 4 12 13

C23-C24 Gallbladder 0 0 0 0 0 0 0 0 1 1 0 3 1

C25 Pancreas 0 0 0 0 0 0 1 4 3 5 7 20 20

C26 Digestive organs unspecified 0 0 0 0 0 0 0 0 1 0 1 2 4

C30-C31 Nasal cavities 0 0 0 0 0 0 1 0 0 3 0 1 3C32 Larynx 0 0 0 0 0 0 1 1 1 5 6 9 18

C33-C34 Lung 0 0 0 0 0 1 0 2 10 14 41 127 136

C37-C39, C45 Respiratory system 0 0 0 0 0 1 0 2 0 1 2 13 16

C40-C41 Bone 0 0 5 2 1 0 2 0 1 0 1 1 2

C43 Malignant melanoma of skin 0 0 0 1 2 3 5 11 15 14 26 21 16

C48 Retroperitoneum and peritoneum 0 0 0 0 0 0 0 0 2 0 1 1 1

C47, C49 Connective Tissue 1 0 1 0 0 0 2 1 2 2 2 5 5

C50 Breast 0 0 0 0 0 0 0 0 1 2 0 1 1

C60, C63 Penis 0 0 0 0 0 0 0 2 0 2 4 0 2

C61 Prostate 0 0 0 0 0 0 0 1 1 9 48 155 267

C62 Testis 2 1 0 1 8 14 20 17 11 6 2 3 3

C64-C66, C68 Kidney 2 0 1 0 0 0 1 6 8 10 18 31 34

C67 Bladder 0 0 0 0 0 0 1 6 1 10 25 44 77

C69 Eye and adnexa 1 0 0 1 0 0 2 0 2 1 2 5 2

C70, C72 Other nervous system 0 2 0 1 0 0 0 0 1 0 0 0 0

C71 Brain 2 4 3 0 4 4 3 5 2 5 8 18 18

C73 Thyroid gland 0 0 0 0 0 0 1 1 2 1 3 2 1

C74-C75 Other endocrine glands 0 1 1 1 1 0 0 0 0 0 1 1 1

C76-C80 Other and unspecified 1 0 0 0 1 1 1 0 5 10 12 26 34 C81 Hodgkin's disease 0 0 1 7 3 2 2 5 1 2 3 4 5

C82-C85, C96 Non Hodgkins Lymphoma 0 1 0 4 3 4 6 7 10 14 15 29 40

C88, C90 Multiple myeloma 0 0 0 0 1 0 1 2 5 4 4 21 7

C91-C95 Total Leukaemia 5 6 4 2 5 2 2 1 7 6 8 9 25

C (exc C44) T otal of all neoplasms (excluding NMSC) 15 15 16 22 31 32 57 87 124 193 349 741 972

NMSC Non-melanoma skin cancer

7


9/12


8

4.2 FEMALES

ICD10 Code Site 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64

C00-C14 Total lip, oral cavity and pharynx 0 0 1 0 0 0 2 0 5 9 9 9 18

C00 Lip 0 0 0 0 0 0 0 0 0 0 0 1 0

C01-C02 Tongue 0 0 0 0 0 0 0 0 0 4 1 4 2

C03-C06 Mouth 0 0 0 0 0 0 0 0 2 3 3 2 4

C07-C08 Salivary glands 0 0 0 0 0 0 1 0 1 0 2 1 2

C09-C10 Oropharynx 0 0 0 0 0 0 1 0 2 2 3 0 5

C11 Nasopharynx 0 0 1 0 0 0 0 0 0 0 0 0 0

C12-C13 Hypopharynx 0 0 0 0 0 0 0 0 0 0 0 1 3

C14 Pharynx unspecified 0 0 0 0 0 0 0 0 0 0 0 0 2

C15 Oesophagus 0 0 0 0 0 1 0 0 2 2 5 8 15

C16 Stomach 0 0 0 0 0 0 0 0 1 6 5 7 12

C17 Small intestine 0 0 0 0 0 0 0 0 0 0 5 0 3

C18-C21 Colorectal 0 0 0 0 2 0 1 7 13 22 47 59 81

C18 Colon 0 0 0 0 0 0 0 6 9 13 29 36 47

C19-C21 Rectum 0 0 0 0 2 0 1 1 4 9 18 23 34

C22 Liver and intrahepatic bile ducts 0 0 0 0 0 0 1 0 1 2 2 2 10

C23-C24 Gallbladder 0 0 0 0 0 0 0 0 0 4 1 1 5

C25 Pancreas 0 0 0 0 0 0 0 2 6 4 9 18 21

C26 Digestive organs unspecified 0 0 0 0 0 0 0 0 0 0 0 0 0

C30-C31 Nasal cavities 0 0 0 0 0 0 0 2 0 1 1 1 0

C32 Larynx 0 0 0 0 0 0 0 1 1 1 1 2 3

C33-C34 Lung 0 0 0 0 0 0 0 4 9 17 41 69 116

C37-C39, C45 Respiratory system 0 0 0 0 0 0 0 1 0 0 0 4 3

C40-C41 Bone 0 0 0 2 0 1 0 0 0 1 1 1 2C43 Malignant melanoma of skin 0 0 1 2 1 7 10 13 17 19 20 32 18

C48 Retroperitoneum and peritoneum 0 0 0 0 0 0 0 0 0 0 0 0 4

C47, C49 Connective Tissue 0 2 0 1 0 1 2 0 2 2 4 3 3

C50 Breast 0 0 0 3 0 6 29 71 142 165 232 288 300

C51-C52 Other female genital 0 0 0 0 0 1 0 1 3 3 3 4 4

C53 Cervix Uteri 0 0 0 0 0 4 12 25 15 17 16 18 11

C54 Corpus Uteri 0 0 0 0 0 1 0 1 8 14 31 52 68

C55 Uterus, part unspecified 0 0 0 0 0 0 0 0 1 2 4 3 1

C56-C57 Ovary 0 0 1 0 3 3 6 9 13 17 22 46 48

C58 Placenta 0 0 0 0 0 0 1 0 0 0 1 0 0

C64-C66, C68 Kidney 2 1 0 0 0 3 2 2 1 6 6 11 19

C67 Bladder 0 0 0 0 0 0 2 1 2 8 7 15 23

C69 Eye and adnexa 2 0 0 0 0 0 0 0 0 0 1 2 4

C70, C72 Other nervous system 0 1 0 1 0 0 0 0 1 0 1 0 0

C71 Brain 2 2 2 2 0 2 2 5 6 5 7 6 5

C73 Thyroid gland 0 0 1 3 3 6 2 4 1 8 5 3 2

C74-C75 Other endocrine glands 1 0 0 0 0 0 0 0 0 1 1 1 1

C76-C80 Other and unspecified 0 1 1 0 0 0 1 5 2 7 13 23 33

C81 Hodgkin's disease 0 0 1 3 2 3 1 3 3 0 4 0 1C82-C85, C96 Non Hodgkins Lymphoma 0 1 0 1 3 0 3 1 7 12 16 22 13

C88, C90 Multiple myeloma 0 0 0 0 0 0 1 1 0 3 6 10 15

C91-C95 Total Leukaemia 6 2 3 2 2 1 2 2 8 4 6 16 11

C (exc C44) Total of all neoplasms (excluding NMSC) 13 10 11 20 16 40 80 161 270 362 533 736 873



10/12


5. TRENDS IN WALES 2000-2004

Incidence figures (all ages)

ICD10 Code Site 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004

C00-C14 Total lip, oral cavity and pharynx 188 183 189 179 217 113 113 113 92 98

C00 Lip 16 25 27 9 19 14 11 7 5 5

C01-C02 Tongue 46 43 33 43 59 22 23 30 16 23

C03-C06 Mouth 36 45 46 55 50 29 30 27 27 29

C07-C08 Salivary glands 24 13 15 13 18 23 18 22 13 12

C09-C10 Oropharynx 33 31 26 24 37 7 12 8 14 15

C11 Nasopharynx 7 4 16 13 5 3 2 4 5 2

C12-C13 Hypopharynx 19 17 18 18 19 11 11 11 6 9

C14 Pharynx unspecified 7 5 8 4 10 4 6 4 6 3

C15 Oesophagus 263 291 250 271 252 187 165 187 159 153

C16 Stomach 374 369 351 373 310 236 219 202 213 218

C17 Small intestine 17 17 17 28 25 16 23 24 22 22

C18-C21 Colorectal 1114 1087 1052 1130 1140 891 870 888 881 919

C18 Colon 658 640 600 678 669 591 572 592 567 623

C19-C21 Rectum 456 447 452 452 471 300 298 296 314 296

C22 Liver and intrahepatic bile ducts 72 76 86 104 107 64 70 59 54 76

C23-C24 Gallbladder 29 42 23 27 28 51 60 40 34 36C25 Pancreas 194 175 204 203 218 201 223 216 236 234

C26 Digestive organs unspecified 8 17 14 13 23 21 17 18 13 27

C30-C31 Nasal cavities 14 11 16 7 14 10 11 11 12 12

C32 Larynx 122 99 108 92 91 21 24 23 16 23

C33-C34 Lung 1287 1323 1248 1283 1312 827 868 848 820 936

C37-C39, C45 Respiratory system 83 90 69 79 95 22 14 22 24 16

C40-C41 Bone 17 18 15 16 25 14 14 6 14 14

C43 Malignant melanoma of skin 164 172 178 196 214 199 203 252 239 233

C48 Retroperitoneum and peritoneum 8 6 5 9 9 10 15 16 10 10

C47, C49 Connective Tissue 45 56 61 51 43 41 34 32 38 40

C50 Breast 13 24 16 16 19 2124 2130 2318 2355 2314

C51-C52 Other female genital - - - - - 92 96 91 79 95

C53 Cervix Uteri - - - - - 164 153 148 158 157

C54 Corpus Uteri - - - - - 325 344 318 338 385

C55 Uterus, part unspecified - - - - - 40 23 27 23 24

C56-C57 Ovary - - - - - 408 383 408 424 369

C58 Placenta - - - - - 1 1 1 2 2

C60, C63 Penis 29 22 22 25 28 - - - - -

C61 Prostate 1647 1771 1798 2002 2288 - - - - -

C62 Testis 75 81 86 112 94 - - - - -

C64-C66, C68 Kidney 221 252 240 232 269 140 133 158 163 168

C67 Bladder 636 662 605 636 676 261 244 248 248 253

C69 Eye and adnexa 25 24 19 29 23 24 21 22 25 19

C70, C72 Other nervous system 7 9 5 2 7 7 9 6 9 7

C71 Brain 149 145 136 125 148 104 101 119 118 95

C73 Thyroid gland 20 16 28 26 25 41 51 58 41 53

C74-C75 Other endocrine glands 7 7 11 5 10 7 14 16 10 14

C76-C80 Other and unspecified 329 303 326 329 342 400 375 372 365 417

C81 Hodgkin's disease 46 56 43 49 44 34 25 31 29 28

C82-C85, C96 Non Hodgkins Lypmphoma 208 251 268 287 278 217 243 252 247 236

C88, C90 Multiple myeloma 139 177 153 164 154 106 136 114 131 129

C91-C95 Total Leukaemia 225 247 265 265 285 181 180 193 191 215

C (exc C44) Total of all neoplasms (excluding NMSC) 7775 8079 7907 8365 8815 7600 7605 7857 7833 8047

MALES FEMALES


9


11/12


6. CRUDE RATES PER 100,000 POPULATION IN WALES 2000-2004

ICD10 Code Site 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004

C00-C14 Total lip, oral cavity and pharynx 13.4 13.0 13.4 12.6 15.1 7.5 7.5 7.5 6.1 6.5

C00 Lip 1.1 1.8 1.9 0.6 1.3 0.9 0.7 0.5 0.3 0.3

C01-C02 Tongue 3.3 3.1 2.3 3.0 4.1 1.5 1.5 2.0 1.1 1.5

C03-C06 Mouth 2.6 3.2 3.3 3.9 3.5 1.9 2.0 1.8 1.8 1.9

C07-C08 Salivary glands 1.7 0.9 1.1 0.9 1.3 1.5 1.2 1.5 0.9 0.8

C09-C10 Oropharynx 2.3 2.2 1.8 1.7 2.6 0.5 0.8 0.5 0.9 1.0

C11 Nasopharynx 0.5 0.3 1.1 0.9 0.3 0.2 0.1 0.3 0.3 0.1

C12-C13 Hypopharynx 1.3 1.2 1.3 1.3 1.3 0.7 0.7 0.7 0.4 0.6

C14 Pharynx unspecified 0.5 0.4 0.6 0.3 0.7 0.3 0.4 0.3 0.4 0.2

C15 Oesophagus 18.7 20.7 17.7 19.0 17.6 12.5 11.0 12.4 10.5 10.1

C16 Stomach 26.6 26.2 24.8 26.2 21.6 15.7 14.6 13.4 14.1 14.4

C17 Small intestine 1.2 1.2 1.2 2.0 1.7 1.1 1.5 1.6 1.5 1.4

C18-C21 Colorectal 79.1 77.2 74.4 79.3 79.5 59.4 57.9 58.8 58.3 60.5

C18 Colon 46.7 45.4 42.4 47.6 46.6 39.4 38.1 39.2 37.5 41.0

C19-C21 Rectum 32.4 31.7 32.0 31.7 32.8 20.0 19.8 19.6 20.8 19.5

C22 Liver and intrahepatic bile ducts 5.1 5.4 6.1 7.3 7.5 4.3 4.7 3.9 3.6 5.0

C23-C24 Gallbladder 2.1 3.0 1.6 1.9 2.0 3.4 4.0 2.6 2.2 2.4

C25 Pancreas 13.8 12.4 14.4 14.2 15.2 13.4 14.9 14.3 15.6 15.4

C26 Digestive organs unspecified 0.6 1.2 1.0 0.9 1.6 1.4 1.1 1.2 0.9 1.8C30-C31 Nasal cavities 1.0 0.8 1.1 0.5 1.0 0.7 0.7 0.7 0.8 0.8

C32 Larynx 8.7 7.0 7.6 6.5 6.3 1.4 1.6 1.5 1.1 1.5

C33-C34 Lung 91.4 93.9 88.3 90.0 91.5 55.2 57.8 56.2 54.2 61.7

C37-C39, C45 Respiratory system 5.9 6.4 4.9 5.5 6.6 1.5 0.9 1.5 1.6 1.1

C40-C41 Bone 1.2 1.3 1.1 1.1 1.7 0.9 0.9 0.4 0.9 0.9

C43 Malignant melanoma of skin 11.6 12.2 12.6 13.7 14.9 13.3 13.5 16.7 15.8 15.3

C48 Retroperitoneum and peritoneum 0.6 0.4 0.4 0.6 0.6 0.7 1.0 1.1 0.7 0.7

C47, C49 Connective Tissue 3.2 4.0 4.3 3.6 3.0 2.7 2.3 2.1 2.5 2.6

C50 Breast 0.9 1.7 1.1 1.1 1.3 141.7 141.9 153.6 155.7 152.4

C51-C52 Other female genital - - - - - 6.1 6.4 6.0 5.2 6.3

C53 Cervix Uteri - - - - - 10.9 10.2 9.8 10.4 10.3

C54 Corpus Uteri - - - - - 21.7 22.9 21.1 22.3 25.4

C55 Uterus, part unspecified - - - - - 2.7 1.5 1.8 1.5 1.6

C56-C57 Ovary - - - - - 27.2 25.5 27.0 28.0 24.3

C58 Placenta - - - - - 0.1 0.1 0.1 0.1 0.1

C60, C63 Penis 2.1 1.6 1.6 1.8 2.0 - - - - -

C61 Prostate 117.0 125.7 127.2 140.4 159.5 - - - - -

C62 Testis 5.3 5.8 6.1 7.9 6.6 - - - - -

C64-C66, C68 Kidney 15.7 17.9 17.0 16.3 18.8 9.3 8.9 10.5 10.8 11.1C67 Bladder 45.2 47.0 42.8 44.6 47.1 17.4 16.2 16.4 16.4 16.7

C69 Eye and adnexa 1.8 1.7 1.3 2.0 1.6 1.6 1.4 1.5 1.7 1.3

C70, C72 Other nervous system 0.5 0.6 0.4 0.1 0.5 0.5 0.6 0.4 0.6 0.5

C71 Brain 10.6 10.3 9.6 8.8 10.3 6.9 6.7 7.9 7.8 6.3

C73 Thyroid gland 1.4 1.1 2.0 1.8 1.7 2.7 3.4 3.8 2.7 3.5

C74-C75 Other endocrine glands 0.5 0.5 0.8 0.4 0.7 0.5 0.9 1.1 0.7 0.9

C76-C80 Other and unspecified 23.4 21.5 23.1 23.1 23.8 26.7 25.0 24.6 24.1 27.5

C81 Hodgkin's disease 3.3 4.0 3.0 3.4 3.1 2.3 1.7 2.1 1.9 1.8

C82-C85, C96 Non Hodgkins Lypmphoma 14.8 17.8 19.0 20.1 19.4 14.5 16.2 16.7 16.3 15.5

C88, C90 Multiple myeloma 9.9 12.6 10.8 11.5 10.7 7.1 9.1 7.6 8.7 8.5

C91-C95 Total Leukaemia 16.0 17.5 18.7 18.6 19.9 12.1 12.0 12.8 12.6 14.2

C (exc C44) Total of all neoplasms (excluding NMSC) 552.2 573.7 559.4 586.9 614.6 507.1 506.5 520.6 517.9 530.1

MALES FEMALES


10


12/12


7. EASR PER 100,000 POPULATION IN WALES 2000-2004

ICD10 Code Site 2000 2001 2002 2003 2004 2000 2001 2002 2003 2004

C00-C14 Total lip, oral cavity and pharynx 11.7 11.1 11.2 10.9 13.1 5.4 5.8 5.5 4.8 5.0

C00 Lip 0.9 1.4 1.5 0.5 1.2 0.6 0.4 0.3 0.2 0.2

C01-C02 Tongue 2.9 2.5 2.0 2.7 3.7 1.2 1.3 1.4 0.9 1.2C03-C06 Mouth 2.3 2.9 2.8 3.3 3.1 1.2 1.5 1.3 1.4 1.4

C07-C08 Salivary glands 1.4 0.7 0.7 0.8 1.0 1.1 1.0 1.1 0.6 0.6

C09-C10 Oropharynx 2.2 2.0 1.6 1.5 2.3 0.4 0.6 0.5 0.9 1.0

C11 Nasopharynx 0.4 0.2 1.0 0.9 0.3 0.2 0.1 0.2 0.3 0.1

C12-C13 Hypopharynx 1.1 1.1 1.1 1.1 1.1 0.5 0.5 0.5 0.3 0.4

C14 Pharynx unspecified 0.4 0.3 0.5 0.2 0.5 0.2 0.3 0.2 0.3 0.1

C15 Oesophagus 15.3 16.3 13.8 14.9 13.3 7.5 6.8 7.1 5.9 5.8

C16 Stomach 20.3 20.5 18.6 19.5 16.3 8.9 8.3 7.8 8.0 7.8

C17 Small intestine 1.0 1.0 1.0 1.7 1.3 0.7 1.2 1.2 0.9 1.0

C18-C21 Colorectal 62.4 60.5 57.4 60.6 59.2 37.1 35.7 36.3 35.6 37.2

C18 Colon 36.5 35.4 32.2 36.0 34.5 24.1 23.4 23.4 22.0 24.8

C19-C21 Rectum 25.9 25.1 25.2 24.7 24.8 13.0 12.3 12.9 13.6 12.5

C22 Liver and intrahepatic bile ducts 4.1 4.2 4.7 5.8 5.7 2.5 2.8 2.6 2.2 3.0

C23-C24 Gallbladder 1.6 2.3 1.3 1.6 1.5 2.1 2.3 1.8 1.3 1.5

C25 Pancreas 11.1 9.8 11.0 10.9 11.5 7.9 8.2 8.4 9.6 9.1

C26 Digestive organs unspecified 0.5 0.8 0.7 0.7 1.2 1.0 0.5 0.5 0.4 0.7

C30-C31 Nasal cavities 0.9 0.7 0.9 0.4 0.8 0.5 0.5 0.5 0.7 0.6

C32 Larynx 7.2 5.7 6.5 5.3 5.1 1.0 1.1 1.1 0.8 1.1

C33-C34 Lung 71.4 71.3 67.2 67.7 68.3 36.8 37.9 36.9 35.9 40.4C37-C39, C45 Respiratory system 4.6 5.4 3.7 4.1 5.2 0.9 0.7 1.1 1.1 0.8

C40-C41 Bone 1.2 1.2 1.0 1.1 1.5 0.9 0.8 0.3 0.8 0.7

C43 Malignant melanoma of skin 10.0 10.8 10.7 11.6 12.7 10.7 10.9 13.9 13.1 12.6

C48 Retroperitoneum and peritoneum 0.5 0.4 0.3 0.5 0.5 0.6 0.9 0.9 0.5 0.4

C47, C49 Connective Tissue 2.8 3.3 3.5 3.0 2.4 2.2 1.6 1.7 2.0 2.0

C50 Breast 0.8 1.3 0.9 0.9 1.0 113.3 113.0 120.7 120.9 118.4

C51-C52 Other female genital - - - - - 3.9 4.1 3.8 3.5 3.6

C53 Cervix Uteri - - - - - 9.4 9.1 8.7 9.3 9.4

C54 Corpus Uteri - - - - - 16.3 17.8 15.7 16.2 19.1

C55 Uterus, part unspecified - - - - - 1.8 1.1 1.1 1.0 1.1

C56-C57 Ovary - - - - - 21.0 19.2 21.1 20.7 18.1

C58 Placenta - - - - - 0.1 0.1 0.1 0.2 0.1

C60, C63 Penis 1.8 1.4 1.3 1.5 1.6 - - - - -

C61 Prostate 88.7 93.8 94.9 103.9 116.5 - - - - -

C62 Testis 5.4 6.0 6.3 8.4 6.9 - - - - -

C64-C66, C68 Kidney 13.1 14.8 13.8 13.1 14.9 6.6 6.4 7.3 7.9 7.8

C67 Bladder 35.5 36.3 32.7 33.8 35.1 11.1 10.2 9.6 10.0 10.1

C69 Eye and adnexa 1.5 1.5 1.1 1.8 1.4 1.0 1.0 1.1 1.5 1.0C70, C72 Other nervous system 0.5 0.5 0.3 0.1 0.4 0.4 0.5 0.3 0.5 0.4

C71 Brain 9.4 9.0 8.3 7.8 8.9 5.8 5.7 6.5 6.1 5.0

C73 Thyroid gland 1.3 1.0 1.8 1.7 1.5 2.3 3.0 3.5 2.4 3.3

C74-C75 Other endocrine glands 0.5 0.5 0.7 0.3 0.6 0.5 0.9 1.0 0.7 0.6

C76-C80 Other and unspecified 17.9 16.6 17.4 17.6 18.0 16.4 13.9 13.4 14.2 15.7

C81 Hodgkin's disease 3.1 3.8 3.0 3.3 2.9 2.1 1.7 2.0 2.0 1.8

C82-C85, C96 Non Hodgkins Lypmphoma 12.8 15.0 15.5 16.5 16.0 10.4 11.0 12.1 11.5 10.6

C88, C90 Multiple myeloma 7.8 9.7 8.3 8.8 8.0 4.6 5.9 4.7 5.1 5.3

C91-C95 Total Leukaemia 13.4 14.2 14.9 14.8 15.4 8.8 7.8 9.0 8.3 9.8

C (exc C44) Total of all neoplasms (excluding NMSC) 440.2 451.0 434.9 454.7 469.3 362.4 358.3 369.6 365.6 370.9

MALES FEMALES

EASR European Age Standardised Rate per 100,000 population


11

wicsu 2006 cancer report

Documents